October 6, 2009
By:Allison Tsai
Leeds, England ? Higher levels of Vitamin D are associated with thinner lesions and a lower rate of relapse in melanoma patients, according to a study published in the Journal of Clinical Oncology.
 |
October 6, 2009
By:Allison Tsai
International report ? Leo Pharma, Denmark, is paying $1 billion in cash to reacquire U.S. rights held by Warner Chilcott for the company?s psoriasis portfolio and dermatology pipeline, Pharma Times reports.
|
October 6, 2009
By:Allison Tsai
Horsham, Pa. ? The U.S. Food and Drug Administration (FDA) has approved the biologic Stelara (ustekinumab, Centocor Ortho Biotech) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy, according to a Centocor press release.
|
October 6, 2009
By:Allison Tsai
New York ? Scientists are heralding Plexxikon?s experimental melanoma drug as a "breakthrough" after it successfully shrank patients? tumors in a clinical trial, according to onemedplace.com.
|
October 6, 2009
National report ? The American Board of Dermatology (ABD) has listed the dates for 2010 examinations.
|
October 1, 2009
By:Louise Gagnon
New York — Patients of color have a unique set of skin concerns, and those concerns need to be addressed while clinicians are treating patients, according to Andrew Alexis, M.D., M.P.H., a dermatologist at St. Luke?s-Roosevelt Hospital in New York. |
October 1, 2009
Los Angeles — The expanding repertoire of cosmetic surgical procedures is providing safe and effective options for addressing aesthetic issues of concern for the aging ethnic face, says Pearl F. Grimes, M.D., director of the Vitiligo and Pigmentation Institute of Southern California, Los Angeles. |
October 1, 2009
Sewickley, Pa. — Chemical peels can be used safely and effectively for a broad range of indications and in patients of all skin types, but achieving success depends on proper skin preparation and matching the peel depth to the indication, says Suzan Obagi, M.D., director of the UPMC Cosmetic Surgery & Skin Health Center, Sewickley, Pa., and assistant professor of dermatology, University of Pittsburgh, Pittsburgh. |
October 1, 2009
By:Bob Roehr
World report — Darker-skinned patients with morphea and related diseases are as likely to benefit from ultraviolet (UV) light therapy as patients with lighter skin. Some clinicians had speculated that the increased level of melanin found in darker skin might impede UV-A1, but that does not appear to be the case. |
| 
Practice Tools
